title: Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
abstract: Resistance of tumor cells to platinum anticancer agents poses a major problem in cancer chemotherapy. One of the mechanisms associated with platinum-based drug resistance is the enhanced capacity of the cell to carry out nucleotide excision repair (NER) on platinum-damaged DNA. Endonucleases XPF and XPG are critical components of NER, responsible for excising the damaged DNA strand to remove the DNA lesion. Here, we investigated possible consequences of down-regulation of XPF and XPG gene expression in osteosarcoma cancer cells (U2OS) and the impact on cellular transcription and DNA repair. We further evaluated the sensitivity of such cells toward the platinum anticancer drugs cisplatin and oxaliplatin.
authors: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, 02139, USA.
authors: Nora
authors: N
authors: Graf
authors: Wee Han
authors: WH
authors: Ang
authors: Guangyu
authors: G
authors: Zhu
authors: MyatNoeZin
authors: M
authors: Myint
authors: Stephen J
authors: SJ
authors: Lippard
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D003603:Cytotoxins / Q000494:pharmacology; D004249:DNA Damage / Q000187:drug effects*; D004260:DNA Repair; D004354:Drug Screening Assays, Antitumor; D004720:Endonucleases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D012516:Osteosarcoma / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D000077150:Oxaliplatin
chemical_list: D000970:Antineoplastic Agents; D003603:Cytotoxins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D004720:Endonucleases; D002945:Cisplatin